دورية أكاديمية
Effect of a 3-Month Single-Drug Approach Using Rivaroxaban for Symptomatic Proximal Deep Vein Thrombosis.
| العنوان: | Effect of a 3-Month Single-Drug Approach Using Rivaroxaban for Symptomatic Proximal Deep Vein Thrombosis. |
|---|---|
| المؤلفون: | Shimizu K; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Sasaki T; Clinical Physiological Function Laboratory, Toho University Sakura Medical Center Sakura Japan., Todani S; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Ito T; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Iwakawa M; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Sugizaki Y; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Sato S; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Nakagami T; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Mikamo H; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan., Kinoshita T; Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan.; Clinical Physiological Function Laboratory, Toho University Sakura Medical Center Sakura Japan. |
| المصدر: | Circulation reports [Circ Rep] 2024 May 22; Vol. 6 (6), pp. 217-222. Date of Electronic Publication: 2024 May 22 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Japanese Circulation Society Country of Publication: Japan NLM ID: 101746642 Publication Model: eCollection Cited Medium: Internet ISSN: 2434-0790 (Electronic) Linking ISSN: 24340790 NLM ISO Abbreviation: Circ Rep Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Tokyo, Japan : The Japanese Circulation Society, [2019]- |
| مستخلص: | Background: Factor Xa inhibitors, such as rivaroxaban, are increasing the convenience of treatment for deep vein thrombosis (DVT). Limited evidence exists regarding clot evaluation at 3 months after treatment for DVT. Methods and Results: We retrospectively analyzed the clinical course of symptomatic proximal DVT in patients who received 3 months of anticoagulation treatment at our hospital. Patients treated with the rivaroxaban single-drug approach were classified as group A (n=42). Patients treated with unfractionated heparin (UFH) or subcutaneous fondaparinux followed by vitamin K antagonist comprised group B (n=60) as an historical cohort. The quantitative ultrasound thrombosis (QUT) score was used to quantify clot burden before and after treatment. No significant differences were observed in patient characteristics between the groups. Serum D-dimer levels in both groups significantly improved after treatment. Clot volume assessed using QUT also reduced significantly in both groups. The QUT score in groups A and B improved from 7.5 [4.8, 12.0] to 3.0 [1.8, 5.0; P=0.000] and 7.0 [4.0, 9.8] to 3.0 [2.0, 5.0; P=0.000], respectively. The change in QUT (∆QUT) was significantly greater in group A compared with group B (-4.5 [-8.25, -2.0] vs. -2.0 [-6.0, 0.0]; P=0.005). Conclusions: We were able to demonstrate the effectiveness of DVT treatment using rivaroxaban over a period of 3 months from onset, in terms of clot regression evaluated using the QUT score. (Copyright © 2024, THE JAPANESE CIRCULATION SOCIETY.) |
| References: | Thromb J. 2016 Jun 13;14:14. (PMID: 27303213) N Engl J Med. 2010 Dec 23;363(26):2499-510. (PMID: 21128814) Intern Med. 2023 Mar 15;62(6):821-831. (PMID: 36328572) N Engl J Med. 2013 Oct 10;369(15):1406-15. (PMID: 23991658) Circ J. 2017 May 25;81(6):855-861. (PMID: 28239036) Thromb J. 2015 Jan 17;13:2. (PMID: 25717286) J Cardiol. 2017 Aug;70(2):163-168. (PMID: 27979674) JAMA. 2020 Nov 03;324(17):1765-1776. (PMID: 33141212) N Engl J Med. 2013 Aug 29;369(9):799-808. (PMID: 23808982) Lancet. 2012 May 12;379(9828):1835-46. (PMID: 22494827) |
| فهرسة مساهمة: | Keywords: Anticoagulant therapy; Deep vein thrombosis; Quantitative ultrasound thrombosis score; Rivaroxaban; Venous thromboembolism |
| تواريخ الأحداث: | Date Created: 20240611 Latest Revision: 20240612 |
| رمز التحديث: | 20240612 |
| مُعرف محوري في PubMed: | PMC11162851 |
| DOI: | 10.1253/circrep.CR-24-0042 |
| PMID: | 38860185 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!